Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate

• Published in: Vaccines (Basel) Vol. 10; no. 6; p. 897
• Main Authors: Ávalos, Ileanet, Lao, Thailin, Rodríguez, Elsa María, Zamora, Yasser, Rodríguez, Alianet, Ramón, Ailyn, Lemos, Gilda, Cabrales, Ania, Bequet-Romero, Monica, Casillas, Dionne, Andújar, Ivan, Espinosa, Luis Ariel, González, Luis Javier, Alvarez, Yanitza, Carpio, Yamila, Estrada, Mario Pablo
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 03-06-2022; MDPI
• Subjects: Antibodies; Antibody response; Antigens; Binding; CD40L protein; Cell culture; Cloning; Coronaviruses; COVID-19; COVID-19 vaccines; Enzymes; Epidemics; Genomes; HEK-293; Hybridization; Immune system; Immunogenicity; Immunoglobulin G; Infections; lentivirus; Morbidity; Plasmids; Proteins; RBD; Receptors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; vaccine; Vaccine development; Vaccines; Viral diseases; Viral infections; Viruses; Cuba; United States > US; Massachusetts
• ISSN: 2076-393X; 2076-393X
• DOI: 10.3390/vaccines10060897

COVID-19 is a respiratory viral disease caused by a new coronavirus called SARS-CoV-2. This disease has spread rapidly worldwide with a high rate of morbidity and mortality. The receptor-binding domain (RBD) of protein spike (S) mediates the attachment of the virus to the host’s cellular receptor. The RBD domain constitutes a very attractive target for subunit vaccine development due to its ability to induce a neutralizing antibody response against the virus. With the aim of boosting the immunogenicity of RBD, it was fused to the extracellular domain of CD154, an immune system modulator molecule. To obtain the chimeric protein, stable transduction of HEK-293 was carried out with recombinant lentivirus and polyclonal populations and cell clones were obtained. RBD-CD was purified from culture supernatant and further characterized by several techniques. RBD-CD immunogenicity evaluated in mice and non-human primates (NHP) indicated that recombinant protein was able to induce a specific and high IgG response after two doses. NHP sera also neutralize SARS-CoV-2 infection of Vero E6 cells. RBD-CD could improve the current vaccines against COVID-19, based in the enhancement of the host humoral and cellular response. Further experiments are necessary to confirm the utility of RBD-CD as a prophylactic vaccine and/or booster purpose.